Janssen Search
Search results
Results from Phase 2 THOR-2 Study Show Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations Treated with BALVERSA® (erdafitinib) Vs Chemotherapy
Oct 21, 2023 Spain Data from Cohort 1 of the Phase 2 THOR-2 study showed oral erdafitinib reduced the risk of disease recurrence or death compared with intravesical standard-of-care chemotherapy MADRID, Spain, October 21, 2023 – The Janssen Pharmaceutical ...
Janssen Submits Application to the European Medicines Agency for RYBREVANT®▼ (amivantamab) in Combination with Chemotherapy for the Treatment of Adult Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer After Failure of Prior Therapy
Nov 27, 2023 Belgium The submission is supported by data from the Phase 3 MARIPOSA-2 study featured in a Late-Breaking Presidential Symposium session at the 2023 ESMO Congress and simultaneously published in Annals of Oncology [1], [2] Amivantamab plus ...
Janssen Submits Application to the European Medicines Agency for RYBREVANT®▼ (amivantamab) in Combination with Chemotherapy for the First-Line Treatment of Adult Patients with Advanced Non-Small Cell Lung Cancer with Activating EGFR Exon20ins Mutations
Oct 06, 2023 Belgium Type II Extension of Indication Application is supported by data from PAPILLON, the first randomised Phase 3 study to read out in patients with NSCLC with EGFR exon 20 insertion mutations [i] BEERSE, BELGIUM, 6 October, 2023 – The ...
Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis
Aug 29, 2024 United States Marks first FDA submission for nipocalimab, an investigational treatment that binds with high affinity and specificity to block FcRn and reduce levels of autoantibodies Filing based on the Phase 3 Vivacity-MG3 program, the ...
Supporting International Women’s Day 2018
Proud of My Company for Igniting the Power of Women Since 1886 Happy International Women’s Day (IWD), everyone! Do you have any idea how proud I am to work for a company that has been championing women for more than 130 years? Extremely! At Johnson & ...
ASCO/EHA 2022
Welcome to the Janssen Oncology ASCO Virtual Newsroom Peter Lebowitz, M.D., Ph.D. Global Therapeutic Area Head Oncology Janssen Research & Development, LLC Tyrone Brewer U.S. President Oncology Janssen Biotech, Inc. Strength in Numbers: How Data ...
Three Things to Know When Initiating Treatment With a Biologic
Three Things to Know When Initiating Treatment With a Biologic As a former practicing physician, I know that patients can sometimes feel overwhelmed when navigating a new treatment. With multiple stakeholders on the journey to accessing a biologic drug ...
UEGW 2020 Newsroom Janssen Immunology R&D
Welcome to the Janssen Immunology UEGW 2020 Newsroom! Please see below for the latest meeting news, a message from our leaders, social feeds, and more information about our progress and commitment to developing innovative medicines for Inflammatory Bowel ...
New RYBREVANT® (amivantamab-vmjw) Data Showed Long-Term Clinical Response and Safety in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations Who Have Failed Prior Platinum-Based Chemotherapy
Mar 29, 2023 Denmark COPENHAGEN, DENMARK, March 29, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new long-term data from the CHRYSALIS study evaluating RYBREVANT ® (amivantamab-vmjw) in patients with advanced non ...
ASH 2020 Newsroom
The American Society of Hematology (ASH) has moved to a virtual platform for the 2020 Annual Meeting, and Janssen Oncology will have a strong showing at ASH with more than 35 company-sponsored presentations highlighting our deep, diverse oncology pipeline ...